IP Verse

Prevention And Treatment Of Synucleinopathic And Amyloidogenic Disease - EP1793855B2

PatentPatent Analysis

EP1793855

ELAN PHARMACEUTICALS
Application Number
EP05783732A
Filing Date
Aug 9, 2005
Status
Patent Maintained As Amended
Dec 17, 2021
Grant Date
Jan 19, 2022
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP2645106B2
EP1991267B1

Bibliography

The patent EP1793855B2 was granted to Elan Pharmaceuticals on Jan 19, 2022 following the initial filing on Aug 9, 2005 under the application number EP05783732A . The current legal status of the patent is Patent Maintained As Amended.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

MATHYS & SQUIREAug 14, 2019ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents